Tiziana life sciences announces allowance by fda for at-home dosing of intranasal foralumab for multiple sclerosis treatment

New york, oct. 18, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa ) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce a significant milestone in the treatment of multiple sclerosis. the u.s. food and drug administration (fda) has allowed multiple sclerosis patients to take home and self-administer intranasal foralumab, a groundbreaking treatment developed by tiziana life sciences. delivery device training materials have been developed and refined in collaboration with the fda, and patients will be trained in the use of the nasal device in accordance with these materials.
TLSA Ratings Summary
TLSA Quant Ranking